Variable/Strata | 3 year estimate | 5 year estimate | 10 year estimate | Log-rank p-value | Wilcoxon p-value |
Symptomatic |
|
|
| 0.5230 | 0.4230 |
No | 34% (11%, 57%) | 34% (11%, 57%) [3] | 11% (8.4%, 31%) [1] |
|
|
Yes | 46% (34%, 59%) [26] | 37% (25%, 49%) [18] | 14% (3.7%, 24%) [5] |
|
|
Pre op renal embolism |
|
|
| 0.4457 | 0.2551 |
No | 49% (23%, 74%) [6] | 49% (23%, 74%) [5] |
|
|
|
Yes | 41% (29%, 53%) [24] | 32% (21%, 44%) [16] | 11% (1.7%, 20%) [4] |
|
|
ASA class 4 vs 2/3 |
|
|
| 0.0555 | 0.1170 |
No | 48% (28%, 68%) [7] | 41% (20%, 62%) [5] | 0% |
|
|
Yes | 19% (0.2%, 38%) [2] | 19% ((0.2%, 38%) [2] | 0% |
|
|
Male gender |
|
|
| 0.4013 | 0.9011 |
No | 41% (29%, 53%) [24] | 36% (24%, 48%) [20] | 19% (8.8%, 29%) [9] |
|
|
Yes | 38% (29%, 47%) [34] | 29% (20%, 38%) [22] | 12% (4.7%, 19%) [8] |
|
|
Age under 60 yrs |
|
|
| 0.7578 | 0.6911 |
No | 40% (31%, 50%) [35] | 34% (25%, 44%) [28] | 15% (7.3%, 22%) [12] |
|
|
Yes | 38% (26%, 49%) [23] | 27% (16%, 38%) [14] | 17% (6.7%, 27%) [5] |
|
|
BMI > 27 |
|
|
| 0.8990 | 0.9045 |
No | 42% (22%, 62%) [7] | 42% (22%, 62%) [6] | 21% (1.4%, 41%) [2] |
|
|
Yes | 52% (32%, 72%) [9] | 46% (±10.4%) | 15% (±10%) |
|
|
Smoking Hx |
|
|
| 0.0831 | 0.2668 |
No | 43% (31%, 56%) [23] | 38% (25%, 50%) [18] | 22% (11%, 34%) [9] |
|
|
Yes | 34% (25%, 44%) [29] | 24% (15%, 34%) [18] | 8.4% (2.0%, 15%) [5] |
|
|
Creatinine > 13 |
|
|
| 0.1117 | 0.2786 |
No | 44% (33%, 55%) [30] | 33% (22%, 44%) [19] | 17% (7.0%, 26%) [7] |
|
|
Yes | 34% (23%, 45%) [20] | 27% (16%, 38%) [15] | 9.8% (1.9%, 18%) [5] |
|
|
Cardiopulmonary bypass |
|
|
| 0.2587 | 0.0955 |
No | 40% (31%, 50%) [37] | 34% (24%, 43%) [30] | 17% (9.5%, 25%) [13] |
|
|
Yes | 37% (25%, 49%) [21] | 28% (16%, 39%) [12] | 10% (1.3%, 19%) [4] |
|
|
Clear cell histology |
|
|
| 0.0090 | <0.01 |
No | 26% (17%, 36%) [20] | 21% (12%, 30%) [14] | 12% (4.6%, 19%) [8] |
|
|
Yes | 52% (41%, 63%) [38] | 42% (31%, 53%) [28] | 18% (8.5%, 27%) [9] |
|
|
Carcomatoid component |
|
|
| 0.5794 | 0.4428 |
No | 40% (32%, 47%) [56] | 32% (24%, 39%) [41] | 15% (8.6%, 21%) [16] |
|
|
Yes | 30% (1.6%, 58%) [2] | 30% (1.6%, 58%) [1] |
|
|
|
Path stage T3b vs T3c |
|
|
| 0.1672 | 0.0642 |
No | 40% (31%, 49%) [40] | 34% (25%, 43%) [32] | 18% (10%, 26%) [14] |
|
|
Yes | 37% (24%, 50%) [18] | 26% (14%, 38%) [10] | 7.9% (0.4%, 16%) [3] |
|
|
Tumor grade of 3/4 vs 1/2 |
|
|
| 0.1269 | 0.0456 |